Immunic (NASDAQ:IMUX) Stock Rating Lowered by Wall Street Zen
by Jessica Moore · The Cerbat GemImmunic (NASDAQ:IMUX – Get Free Report) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Sunday.
Other equities analysts also recently issued reports about the company. upgraded Immunic to a “strong-buy” rating in a research report on Tuesday, February 3rd. Stifel Nicolaus set a $2.50 price target on shares of Immunic and gave the stock a “buy” rating in a research report on Thursday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunic in a research note on Monday, December 29th. Guggenheim began coverage on shares of Immunic in a research report on Tuesday, March 24th. They set a “buy” rating and a $7.00 price objective for the company. Finally, D. Boral Capital downgraded shares of Immunic from a “buy” rating to a “hold” rating in a research note on Wednesday, April 15th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Immunic presently has an average rating of “Moderate Buy” and a consensus price target of $5.64.
View Our Latest Analysis on Immunic
Immunic Price Performance
NASDAQ:IMUX opened at $0.96 on Friday. Immunic has a one year low of $0.51 and a one year high of $1.51. The company has a market cap of $124.59 million, a PE ratio of -1.36 and a beta of 1.37. The firm’s 50 day simple moving average is $1.09 and its 200 day simple moving average is $0.84.
Immunic’s stock is going to reverse split on Monday, April 27th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, April 26th.
Immunic (NASDAQ:IMUX – Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02). Equities research analysts expect that Immunic will post -0.39 EPS for the current year.
Hedge Funds Weigh In On Immunic
Institutional investors have recently added to or reduced their stakes in the business. Qube Research & Technologies Ltd acquired a new position in shares of Immunic during the 3rd quarter valued at $29,000. Two Sigma Investments LP bought a new stake in Immunic in the third quarter valued at $52,000. HB Wealth Management LLC acquired a new position in shares of Immunic during the third quarter valued at about $81,000. Seven Fleet Capital Management LP acquired a new position in shares of Immunic during the fourth quarter valued at about $83,000. Finally, Virtu Financial LLC bought a new position in shares of Immunic during the 3rd quarter worth about $99,000. 51.82% of the stock is owned by institutional investors and hedge funds.
About Immunic
Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.
Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.